Biogen is making “strong progress” with enrollment in the AMETHYST study, a Phase 2/3 clinical trial testing the company’s experimental therapy litifilimab (BIIB059) in people with cutaneous lupus erythematosus (CLE). That’s according to Diana Gallagher, MD, Biogen’s…